Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.

Milat F, Goh S, Gani LU, Suriadi C, Gillespie MT, Fuller PJ, Teede HJ, Strickland AH, Allan CA.

Bone. 2013 Aug;55(2):305-8. doi: 10.1016/j.bone.2013.04.012. Epub 2013 Apr 25.

PMID:
23685544
2.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.

Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Epub 2013 May 13. Review.

3.

The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases.

Lechner B, DeAngelis C, Jamal N, Emmenegger U, Pulenzas N, Giotis A, Sheehan P, Tsao M, Bedard G, Chow E.

Support Care Cancer. 2014 Jul;22(7):1765-71. doi: 10.1007/s00520-014-2142-2. Epub 2014 Feb 11.

PMID:
24515277
4.

Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?

Ho JW, Sundar S.

Clin Genitourin Cancer. 2012 Mar;10(1):50-3. doi: 10.1016/j.clgc.2011.11.004. Epub 2012 Jan 14. No abstract available.

PMID:
22245101
5.

A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.

Laskowski LK, Goldfarb DS, Howland MA, Kavcsak K, Lugassy DM, Smith SW.

J Med Toxicol. 2016 Sep;12(3):305-8. doi: 10.1007/s13181-016-0543-y. Epub 2016 Mar 17.

6.
7.

Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency.

Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF.

Am J Emerg Med. 2013 Apr;31(4):756.e1-2. doi: 10.1016/j.ajem.2012.11.011. Epub 2013 Feb 8.

PMID:
23399342
8.

Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.

Watkins KR, Rogers JE, Atkinson B.

Support Care Cancer. 2015 Jun;23(6):1657-62. doi: 10.1007/s00520-014-2521-8. Epub 2014 Nov 25.

PMID:
25421444
9.

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

Fizazi K, Bosserman L, Gao G, Skacel T, Markus R.

J Urol. 2013 Jan;189(1 Suppl):S51-7; discussion S57-8. doi: 10.1016/j.juro.2012.11.022.

PMID:
23234632
10.

Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.

Autio KA, Farooki A, Glezerman IG, Chan A, Schneider CW, Barr HC, Seyboth BM, Kampel LJ, Danila DC, Rathkopf DE, Slovin SF, Scher HI, Morris MJ.

Clin Genitourin Cancer. 2015 Aug;13(4):e305-9. doi: 10.1016/j.clgc.2014.11.008. Epub 2014 Nov 22. No abstract available.

11.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

PMID:
21343556
12.

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.

Support Care Cancer. 2016 Jan;24(1):447-55. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3. Erratum in: Support Care Cancer. 2015 Oct 19;:.

13.

Management of bone metastases in refractory prostate cancer--role of denosumab.

Paller CJ, Carducci MA, Philips GK.

Clin Interv Aging. 2012;7:363-72. doi: 10.2147/CIA.S27930. Epub 2012 Sep 17. Review.

14.

Denosumab osteonecrosis of the mandible: a new entity? A case report.

Pichardo SE, Kuypers SC, van Merkesteyn JP.

J Craniomaxillofac Surg. 2013 Jun;41(4):e65-9. doi: 10.1016/j.jcms.2012.10.014. Epub 2012 Dec 21.

PMID:
23265807
15.

[The clinical merit of anti-RANKL antibody denosumab in prostate cancer].

Akaza H, Tsukamoto T, Suzuki K, Namiki M, Ozono S, Naitodept S.

Gan To Kagaku Ryoho. 2012 Feb;39(2):207-12. Japanese.

PMID:
22333629
16.

[Denosumab-induced severe hypocalcemia].

Barrasa Rodríguez MC, Ulla Anes M, Perez Rojas F, García Melcón G.

Med Clin (Barc). 2012 Jul 21;139(5):227-8. doi: 10.1016/j.medcli.2012.01.010. Epub 2012 Mar 6. Spanish. No abstract available.

PMID:
22397979
17.
18.

Identification of the risk factors associated with hypocalcemia induced by denosumab.

Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, Minakuchi K.

Biol Pharm Bull. 2013;36(10):1622-6. Epub 2013 Aug 9.

19.

High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.

Kinoshita Y, Arai M, Ito N, Takashi Y, Makita N, Nangaku M, Shinoda Y, Fukumoto S.

Endocr J. 2016 May 31;63(5):479-84. doi: 10.1507/endocrj.EJ16-0003. Epub 2016 Feb 9.

20.

A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment.

Blackley S, Anderson K, Berg J.

J R Coll Physicians Edinb. 2015;45(2):133-5. doi: 10.4997/JRCPE.2015.209.

PMID:
26181529

Supplemental Content

Support Center